“As we come to the end of 2018, we are very pleased with the technology accomplishments that we have achieved over the past several months,” stated Robert J. Wagner, CEO of OneLife Technologies Corp. “By completing the acquisition of key technology assets, receiving FCC certification and PTCRB approval, along with successful in-market testing, we can now begin finalizing the launch of our stand-alone wearable with our advanced data collection and monitoring device platform for the global health and medical marketplaces,” added Wagner.
Summary of Recent Developments:
Finalized Yinuo Asset Acquisitions
OneLife Technologies has completed the acquisition of Yinuo IP, Intellectual Property, and other related assets regarding the wearable and Tricorder technologies. The Company is now able to protect any new technology and products, which it may introduce to the market in 2019, against any competitive infringement. The acquisition of these assets was finalized on November 7, 2018 when the Registration Certificate of Technology Export Contract was stamped by the Chinese Government Authority (Shenzhen Economy, Trade and Information Committee).
Completion of FCC Certification for Health Watch
The FCC has decided that all devices that are intentional radiators in the FCC frequency spectrum must receive an FCC certification prior to being marketed for sale in the US. Compliance Testing is mandated to test a device to the appropriate FCC Standards or FCC Rule Part to validate compliance. The completed FCC test report is then submitted to a TCB (Telecommunication Certification Body) for review and approval. The manufacturer then receives an FCC Grant enabling the sale of the device in the US market. OneLife Technologies, Corp. completed/received their FCC Certifications on November 28, 2018.
Completion of PTCRB Approval for Health Watch
PTCRB is a certification organization established in 1997 by leading wireless operators to define test specifications and methods to ensure device interoperability on global wireless networks. With PTCRB certification, operators and device manufacturers are confident of a device’s interoperability with mobile networks. Member operators are committed to ensuring device quality through a rigorous certification process. Without PTCRB certification, manufacturers run the risk that their devices will be blocked on wireless networks. OneLife Technologies Corp. completed and received PTCRB approval on December 3, 2018.
“As a result of having completed the IP acquisition, FCC certification and PTCRB approval, we are now poised to deliver to the marketplace the first wrist-worn wearable that is a cellular enabled, stand-alone, LTE-M connected instrument. In addition, the OneLife wearable product will be a networked-certified device with up to a 5-day battery life that can be integrated not only with other devices through our custom Bluetooth protocol, but also with other relevant software platforms. We are very excited to continue the execution of our business plan in 2019 as the OneLife Team brings to market its ‘Hub-of-Care’ health and medical technologies while continuing its focus on becoming a leader in mobile health and medical technology innovation,” added Wagner.
ABOUT ONELIFE TECHNOLOGIES CORP.
OneLife Technologies Corp. is a mobile medical software/data collection company with a suite of proprietary, patented, medical grade wearable tracking technologies designed to provide patients, physicians, nursing homes, and hospitals with 24/7 real-time centralized, personal, comprehensive health data. For additional information, visit www.onelifetc.com.
OneLife Technologies Corp.
FORWARD LOOKING STATEMENT
This news release includes forward-looking statements that reflect OneLife Technologies Corp. current expectations about its future results, performance, prospects and opportunities OneLife Technologies Corp. has tried to identify these forward-looking statements by using words and phrases such as "may", "will", "expects", "anticipates", "believes", "intends", "estimates", "should", "typical", "we are confident" or similar expressions. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties and other factors that could cause the Company's actual results, performance, prospects of opportunities for the remainder of 2018 and beyond to differ materially from those expressed in, or implied by, these forward-looking statements.